白云山(600332.SH)：选择性RET小分子抑制剂BYS10片进入关键性临床试验

Core Viewpoint - Baiyunshan Pharmaceutical Group's subsidiary, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., has received feedback from the National Medical Products Administration (NMPA) regarding its selective RET small molecule inhibitor, BYS10 tablets, which are undergoing clinical trials for treating advanced solid tumors with RET gene fusions or mutations [1] Group 1 - The clinical study is an open-label, multi-center Phase I/II trial aimed at evaluating the safety, tolerability, pharmacokinetic characteristics, and efficacy of BYS10 tablets [1] - The trial specifically targets advanced solid tumors associated with RET gene fusions or mutations [1]